Imunon (NASDAQ:IMNN) Price Target Cut to $17.00 by Analysts at D. Boral Capital

Imunon (NASDAQ:IMNN) had its price target reduced by D. Boral Capital from $29.00 to $17.00 in a research report sent to investors on Tuesday morning,Benzinga reports. D. Boral Capital currently has a buy rating on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of Imunon in a research note on Wednesday, March 26th.

Imunon Trading Down 1.9%

Shares of IMNN stock opened at $0.80 on Tuesday. The business’s 50 day moving average is $0.90 and its two-hundred day moving average is $0.88. Imunon has a twelve month low of $0.64 and a twelve month high of $3.65. The company has a market capitalization of $11.70 million, a P/E ratio of -0.42 and a beta of 1.75.

Imunon (NASDAQ:IMNN) last announced its earnings results on Monday, May 12th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.07. As a group, equities analysts predict that Imunon will post -1.68 earnings per share for the current fiscal year.

Institutional Trading of Imunon

A hedge fund recently raised its stake in Imunon stock. Geode Capital Management LLC lifted its holdings in Imunon, Inc. (NASDAQ:IMNN) by 10.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 139,505 shares of the company’s stock after buying an additional 13,570 shares during the quarter. Geode Capital Management LLC owned 0.96% of Imunon worth $133,000 as of its most recent SEC filing. 4.47% of the stock is currently owned by institutional investors.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.